Open AccessA case for improving frail patient outcomes in multiple myeloma with phenotype‐driven personalized medicine
Author(s) -
Reiman Lauren T.,
Walker Zachary J.,
Babcock Lyndsey R.,
Forsberg Peter A.,
Mark Tomer M.,
Sherbenou Daniel W.
Publication year - 2021
Publication title -
aging and cancer
Language(s) - English
Resource type - Journals
ISSN - 2643-8909
DOI - 10.1002/aac2.12022
Subject(s) - medicine , personalized medicine , precision medicine , intensive care medicine , disease , multiple myeloma , drug , population , oncology , bioinformatics , pharmacology , pathology , environmental health , biology
Abstract The treatment of older persons with cancer is fraught by a delicate balance of targeting the disease while avoiding treatment‐related complications. “Personalized,” or “precision” medicine approaches can ease this problem through more efficacious and less toxic treatments. Multiple myeloma epitomizes the struggle to balance treatment options and their complications, for it is an incurable disease afflicting a predominantly aged population, and treatment is administered on a continuous schedule with little or no breaks. Over the last two decades, advances in drug development have improved outcomes for younger, fit patients, but older, frail patients have not realized the same benefit. This could be related to the benefits of three drug combinations, when frail patients can often tolerate only two drugs at a time. In myeloma, personalized approaches have lagged behind some other malignancies due to its genetic complexity and a paucity of abnormalities with associated targeted therapies. In contrast, the disease is managed with an array of drugs that target phenotypic characteristics common in malignant plasma cells. To address the unmet need for personalized medicine in myeloma, we developed a functional approach by profiling the sensitivity of patients’ myeloma to clinically available drugs. Through this, we observed that receiving at least two effective drugs portended better outcomes, leaving those patients who can only tolerate two drug regimens without room for error. We now describe a frail patient's case and their drug sensitivity profile to illustrate how personalized treatment could have led to an improved disease course. Personalized treatment could provide the greatest survival improvements to older adults with cancers, such as multiple myeloma, through avoiding undertreatment, limiting attrition through subsequent lines of therapy, reducing exposure to ineffective drugs and streamlining the management of relapses. Exploring these avenues is imperative to closing the gap of cancer‐related mortality in older and frail persons.